Browsing by Author "Lu, X."

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    ItemOpen Access
    Detecting user types in object ranking decisions
    (ACM, 2009-10) Lu, X.; Schaal, Markus; Adalı, S.; Raju, A. K.
    With the emergence of Web 2.0 applications, where information is not only shared across the internet, but also syndicated, evaluated, selected, recombined, edited, etc., quality emergence by collaborative effort from many users becomes crucial. However, users may have low expertise, subjective views, or competitive goals. Therefore, we need to identify cooperative users with strong expertise and high objectivity. As a first step towards this aim, we propose criteria for user type classification based on prior work in psychology and derived from observations in Web 2.0. We devise a statistical model for many different user types, and detection methods for those user types. Finally, we evaluate and demonstrate both model and detection methods by means of an experimental setup. Copyright 2009 ACM.
  • Thumbnail Image
    ItemOpen Access
    p53 polymorphism influences response in cancer chemotheraphy via modulation of p73-dependent apoptosis
    (Elsevier, 2003-04) Bergamaschi, D.; Gasco, M.; Hiller, L.; Sullivan, A.; Syed, N.; Trigiante, G.; Yulug, I.; Merlano, M.; Numico, G.; Comino, A.; Attard, M.; Reelfs, O.; Gusterson, B.; Bell, A. K.; Heath, V.; Tavassoli, M.; Farrell, P. J.; Smith, P.; Lu, X.; Crook, T.
    Intact p73 function is shown to be an important determinant of cellular sensitivity to anticancer agents. Inhibition of p73 function by dominant-negative proteins or by mutant p53 abrogates apoptosis and cytotoxicity induced by these agents. A polymorphism encoding either arginine (72R) or proline (72P) at codon 72 of p53 influences inhibition of p73 by a range of p53 mutants identified in squamous cancers. Clinical response following cisplatin-based chemo-radiotherapy for advanced head and neck cancer is influenced by this polymorphism, cancers expressing 72R mutants having lower response rates than those expressing 72P mutants. Polymorphism in p53 may influence individual responsiveness to cancer therapy.